Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 1Non Hematologic Cancers 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Low Grade Serous Ovarian Cancer 1Carcinoma, Ovarian Epithelial 1Adenoma 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × defactinib × Clear all
NCT06682572 2025-12-17

RAMP201J

Verastem, Inc.

Phase 2 Active not recruiting
16 enrolled
Gynecologic

Ovarian Neoplasms

NCT04625270 2025-01-29

RAMP 201

Verastem, Inc.

Phase 2 Active not recruiting
225 enrolled 1 FDA
Gynecologic

Ovarian Neoplasms

NCT01778803 2017-05-17

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Verastem, Inc.

Phase 1 Completed
22 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡